HALO AP

New zero-click preprocessing automatically identifies invasive carcinoma and excludes DCIS, LCIS, and control tissue before ER, PR, HER2, and Ki67 quantification. Shown here is the HALO Breast IHC AI out put of a stained HER2 slide with AI overlay only in the regions of invasive cancer.

Indica Labs Advances Breast Cancer AI with Zero-Click Tissue Classification Prior to Biomarker Analysis

HALO AP, News, Press Releases / , , , , , , ,

Albuquerque, NM, July 28, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced new intelligent tissue classification capabilities for HALO Breast IHC AI, its AI-powered breast biomarker quantification suite, seamlessly deployed in HALO AP®. This enhanced new version introduces fully automated identification and exclusion of positive control tissue, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and areas of benign tissue prior to biomarker analysis. This zero-click preprocessing and tissue classification workflow represents a critical step in ensuring accurate and reproducible AI outputs.

Indica Labs Advances Breast Cancer AI with Zero-Click Tissue Classification Prior to Biomarker Analysis Read More »

The latest HALO AP® update is a transformative new version that introduces intelligent workflow orchestration, traceability, and multi-site collaboration to support modern diagnostic environments.

HALO AP 2.5 Advances Digital Pathology with Enhanced Automation, Collaboration, and Scalability

HALO AP, News, Press Releases / , ,

Albuquerque, NM, July 14, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced a new software release designed to streamline and scale digital pathology workflows through enhanced automation, collaboration, and system transparency.

HALO AP 2.5 Advances Digital Pathology with Enhanced Automation, Collaboration, and Scalability Read More »

Prostate Macrodissect AI enables pathologists to identify and quantify tumor-rich regions in prostate specimens with precision. Improving macrodissection accuracy, maximizing NGS tumor content, and reducing QNS failures, a critical advancement in the molecular profiling of the most commonly diagnosed cancer in men.

Indica Labs Expands into Prostate Cancer, Improving NGS ConfidenceThrough Precise Tumor Quantification

HALO AP, News, Press Releases / , ,

Albuquerque, NM, June 30, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the launch of Prostate Macrodissect AI, a clinically validated algorithm designed to automate and quantify tumor content in FFPE prostate tissue specimens. Prostate Macrodissect AI is designed to operate in concert with Indica Labs’ broader HALO Clinical AI suite, enabling laboratories to build end-to-end AI-powered prostate cancer workflows from automated tumor detection and Gleason grading assistance through to optimized macrodissection and genomic test preparation within a single, validated digital pathology platform.

Indica Labs Expands into Prostate Cancer, Improving NGS ConfidenceThrough Precise Tumor Quantification Read More »

AI powered companion diagnostics reshaping the future of precision medicine.

Indica Labs Unveils AI-Powered Companion Diagnostics Offering Ahead of ASCO 2026

HALO AP, News, Press Releases / , ,

Albuquerque, NM, May 27, 2026 – Indica Labs, the global leader in AI-powered digital pathology solutions, today announced a major expansion of its companion diagnostics (CDx) capabilities, positioning the company at the forefront of precision medicine innovation ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Indica Labs Unveils AI-Powered Companion Diagnostics Offering Ahead of ASCO 2026 Read More »

A partnership Leica Biosystems, Indica Labs, and Lunit that will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, supporting scalable and consistent biomarker quantification through computational pathology tools. The first product is an AI-powered Lunit SCOPE algorithm designed for Leica Biosystems’ PD-L1 primary antibody (CAL10).

Industry Leaders Leica Biosystems, Indica Labs and Lunit Partner to Develop AI-Powered Computational Pathology Assays for PD-L1 and Emerging Biomarkers

HALO AP, News, Press Releases /

VISTA, California, ALBUQUERQUE, New Mexico, and SEOUL, South Korea — May 26, 2026 — Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Indica Labs, a global leader in AI-powered digital pathology software, today announced a strategic collaboration with Lunit (KRX:328130.KQ), a leading provider of AI solutions for cancer diagnostics and therapeutics, to develop AI-powered image analysis algorithms. The partnership will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, supporting scalable and consistent biomarker quantification through computational pathology tools. The first product is an AI-powered Lunit SCOPE algorithm designed for Leica Biosystems’ PD-L1 primary antibody (CAL10). The new algorithm, Lunit SCOPE PD-L1 CAL10 NSCLC1, is now available through Leica Biosystems’ Aperio AI Store.

Industry Leaders Leica Biosystems, Indica Labs and Lunit Partner to Develop AI-Powered Computational Pathology Assays for PD-L1 and Emerging Biomarkers Read More »

Indica Labs, HALO AP Dx, FDA 510(k)-cleared digital pathology platform displayed with the Aperio GT 450 DX Scanner for in vitro diagnostic use.

Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems

Clinical, HALO AP, HALO AP Dx, News, Press Releases / , ,

ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.

Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems Read More »

Multiple South West London Pathology Trusts Select Indica Labs and Leica Biosystems for Advancing Digital Pathology in Clinical Practice

HALO AP, News, Press Releases /

Albuquerque, NM, September 24, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announce today that multiple trusts within the South West London Pathology network have chosen the powerful combination of Leica Biosystems Aperio GT 450 DX scanners and Indica Labs’ HALO AP® for digital pathology adoption.

Multiple South West London Pathology Trusts Select Indica Labs and Leica Biosystems for Advancing Digital Pathology in Clinical Practice Read More »

Free Demo
Free Demo
Scroll to Top